Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

MLA

Lili Cheng, et al. “Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.” Frontiers in Immunology, vol. 12, July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2ed32cff88ce020f98476d27e76cdd5c&authtype=sso&custid=ns315887.

APA

Lili Cheng, Meng-Ke Liu, Wei-Li Zhao, Shu Cheng, Li Wang, Ying Qian, Yan Wang, Chao-Fu Wang, Qi Song, Hongmei Yi, & Pengpeng Xu. (2021). Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide. Frontiers in Immunology, 12.

Chicago

Lili Cheng, Meng-Ke Liu, Wei-Li Zhao, Shu Cheng, Li Wang, Ying Qian, Yan Wang, et al. 2021. “Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide.” Frontiers in Immunology 12 (July). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2ed32cff88ce020f98476d27e76cdd5c&authtype=sso&custid=ns315887.